A recent report examined the field of pharmacogenomics and its application to psychotropic medications; specifically, the gene-drug interactions between CYP2D6, CYP3A4, and CYP1A2 with antipsychotics. The report found that CYP2D6 phenotypes impact plasma concentration levels and therapeutic outcomes for various antipsychotics, CYP3A4 has shown significant interactions with quetiapine, and CYP1A2 doesn’t display significant differences in pharmacokinetics for drugs like clozapine or olanzapine.

The report concluded that significant organizations such as the Clinical Pharmacogenetics Implementation Consortium, FDA, and Dutch Pharmacogenetics Working Group recognize the importance of using pharmacogenomics, which can be essential in guiding dosing and minimizing the risk of adverse effects with antipsychotic medications due to its influence on pharmacokinetics.

Reference: Mitaly A. Pharmacogenomics Update: Working Group Guideline for Gene-Drug Interactions Between CYP2D6, CYP3A4, and CYP1A2 With Antipsychotics. Pharmacy Times. Published July 24, 2023. Accessed October 4, 2023. https://www.pharmacytimes.com/view/pharmacogenomics-update-working-group-guideline-for-gene-drug-interactions-between-cyp2d6-cyp3a4-and-cyp1a2-with-antipsychotics